PJSC Ozon Pharmaceuticals (OZPH.ME)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | RUB bn | - | 18 | 19 | 20 | 26 | 32 | 33 | - |
| Operating profit | RUB bn | 11 | 12 | ||||||
| Net profit | RUB bn | - | 4 | 4 | 4 | 5 | 6 | 8 | - |
| EPS reported | RUB | 5.44 | 4.04 | ||||||
| Operating cashflow per share | RUB | 2.87 | 5.14 | ||||||
| Capex per share | RUB | 1.73 | 2.16 | ||||||
| FCF per share | RUB | 1.14 | 2.97 | ||||||
| Free cash flow | RUB bn | - | 5 | ||||||
| Net debt | RUB bn | - | 5 | ||||||
| Book value equity | RUB bn | - | 36 | ||||||
| Book value per share | RUB | 29.25 | 31.04 | ||||||
| Number of shares | m | 1,135 | 1,159.85 | ||||||
| DPS (TTM paid) | RUB | 0.95 | 1.47 |
Financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 9.46 | - | ||||||
| P/B LTM | x | 1.76 | 1.62 | ||||||
| P/S LTM | x | 1.85 | 1.76 | ||||||
| P/FCF LTM | x | 45.14 | 11.80 | ||||||
| EV/EBITDA LTM | x | 5.77 | 5.18 | ||||||
| EV/Sales LTM | x | 2.14 | 0.34 | ||||||
| Earnings Yield LTM | % | +10.57% | +12.66% | ||||||
| FCF Yield | % | +2.22% | +8.47% | ||||||
| Quality | |||||||||
| ROE | % | +18.58% | +29.88% | ||||||
| ROIC | % | +17.93% | +19.82% | ||||||
| Operating margin | % | +34.13% | +34.13% | ||||||
| Gross margin | % | +47.72% | +47.72% | ||||||
| FCF/Sales | % | +4.09% | +10.68% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +21.97% | -9.42% | ||||||
| Sales Growth YoY | % | +23.57% | +29.67% | ||||||
| Net Income Growth YoY | % | +33.80% | +67.10% | ||||||
| FCF Growth | % | - | +46.65% | ||||||
| Operating Profit Growth | % | +35.77% | +47.27% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.84% | 0.00% | ||||||
| Dividend Growth | % | - | +0.61% | ||||||
| Payout Ratio | % | +32.66% | +17.40% | ||||||
| FCF/Debt | x | - | 0.61 | ||||||
| Net Debt/EBITDA | x | 0.78 | 0.86 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +20.22% | +23.63% | ||||||
| Net debt/Equity | x | - | 0.14 | ||||||
| Gross debt/equity | x | - | 0.22 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PJSC Ozon Pharmaceuticals manufactures and sells pharmaceutical products. It offers traditional small molecular pharmaceuticals; and chemical pharmaceuticals/drugs products for oncological and autoimmune diseases, as well as biotechnological products. The company was founded in 2001 and is based in Zhigulyovsk, Russia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PJSC Ozon Pharmaceuticals (OZPH.ME)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PJSC Ozon Pharmaceuticals manufactures and sells pharmaceutical products. It offers traditional small molecular pharmaceuticals; and chemical pharmaceuticals/drugs products for oncological and autoimmune diseases, as well as biotechnological products. The company was founded in 2001 and is based in Zhigulyovsk, Russia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free